At R&D Directions Insider, Michael Christel speaks with Bert Spilker, who has worked at a variety of drug companies and has written books on drug development, about mergers and acquisitions, clinical trial reform, transparency, and more. "The issue of transparency has been focused on the industry, and during the '90s and early part of this decade, the industry fought this quite strongly," Spilker says, adding that industry's position has changed. "Today, the industry has accepted the concept of trial registries and is also providing at least a summary of the results of trials on company websites or in a more centralized way."
Talking Drug Development
Jun 16, 2009